Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Telomerase reverse transcriptase | 0.571 | 0.7263 | 1 |
Echinococcus granulosus | TGF beta signal transducer SmadC | 0.0017 | 0.0001 | 1 |
Toxoplasma gondii | RNA-directed DNA polymerase | 0.2146 | 0.2716 | 0.5 |
Schistosoma mansoni | smad1 5 8 and | 0.0017 | 0.0001 | 0.0217 |
Brugia malayi | Smad1 | 0.0017 | 0.0001 | 0.0001 |
Brugia malayi | MH1 domain containing protein | 0.0017 | 0.0001 | 0.0001 |
Brugia malayi | MH2 domain containing protein | 0.0017 | 0.0001 | 0.0001 |
Loa Loa (eye worm) | hypothetical protein | 0.0053 | 0.0046 | 0.1538 |
Echinococcus granulosus | Smad4 | 0.0017 | 0.0001 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0036 | 0.0025 | 1 |
Schistosoma mansoni | smad1 5 8 and | 0.0017 | 0.0001 | 0.0217 |
Loa Loa (eye worm) | hypothetical protein | 0.0036 | 0.0025 | 0.0826 |
Echinococcus multilocularis | Smad4 | 0.0017 | 0.0001 | 1 |
Giardia lamblia | Telomerase catalytic subunit | 0.2146 | 0.2716 | 0.5 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0053 | 0.0046 | 0.0063 |
Loa Loa (eye worm) | Smad1 | 0.0017 | 0.0001 | 0.0018 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0053 | 0.0046 | 0.1538 |
Schistosoma mansoni | smad | 0.0017 | 0.0001 | 0.0217 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0036 | 0.0025 | 0.0034 |
Echinococcus multilocularis | smad | 0.0017 | 0.0001 | 1 |
Schistosoma mansoni | TGF-beta signal transducer Smad2 | 0.0017 | 0.0001 | 0.0217 |
Echinococcus granulosus | mothers against decapentaplegic 5 | 0.0017 | 0.0001 | 1 |
Trypanosoma cruzi | telomerase reverse transcriptase, putative | 0.2146 | 0.2716 | 0.5 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0053 | 0.0046 | 0.0063 |
Trypanosoma cruzi | telomerase reverse transcriptase, putative | 0.2146 | 0.2716 | 0.5 |
Echinococcus multilocularis | TGF beta signal transducer SmadC | 0.0017 | 0.0001 | 1 |
Plasmodium vivax | telomerase reverse transcriptase, putative | 0.2146 | 0.2716 | 0.5 |
Brugia malayi | MH2 domain containing protein | 0.0251 | 0.0299 | 0.0412 |
Schistosoma mansoni | smad1 5 8 and | 0.0017 | 0.0001 | 0.0217 |
Plasmodium falciparum | telomerase reverse transcriptase | 0.2146 | 0.2716 | 0.5 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0251 | 0.0299 | 1 |
Loa Loa (eye worm) | MH1 domain-containing protein | 0.0017 | 0.0001 | 0.0018 |
Schistosoma mansoni | Smad4 | 0.0017 | 0.0001 | 0.0217 |
Leishmania major | telomerase reverse transcriptase, putative | 0.2146 | 0.2716 | 0.5 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0017 | 0.0001 | 0.0018 |
Echinococcus granulosus | smad | 0.0017 | 0.0001 | 1 |
Trypanosoma brucei | telomerase reverse transcriptase | 0.2146 | 0.2716 | 0.5 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0251 | 0.0299 | 1 |
Brugia malayi | MH1 domain containing protein | 0.0017 | 0.0001 | 0.0001 |
Brugia malayi | MH2 domain containing protein | 0.0017 | 0.0001 | 0.0001 |
Echinococcus multilocularis | mothers against decapentaplegic 5 | 0.0017 | 0.0001 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
MIC (functional) | = 0.2 ug ml-1 | In vitro minimum inhibitory concentration against Escherichia coli NIHJ JC-2 | ChEMBL. | 15857125 |
MIC (functional) | = 0.2 ug ml-1 | In vitro minimum inhibitory concentration against Escherichia coli NIHJ JC-2 | ChEMBL. | 15857125 |
MIC (functional) | = 1.56 ug ml-1 | In vitro minimum inhibitory concentration against Pseudomonas aeruginosa IID1210 | ChEMBL. | 15857125 |
MIC (functional) | = 3.13 ug ml-1 | In vitro minimum inhibitory concentration against Staphylococcus aureus Smith | ChEMBL. | 15857125 |
MIC (functional) | = 12.5 ug ml-1 | In vitro minimum inhibitory concentration against Streptococcus pneumoniae type III | ChEMBL. | 15857125 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.